drugset / Trial / NCT07231900

Sodium Bicarbonate in Intra-dialytic Hypertension in Chronic Hemodialysis Patients

NCT07231900

Phase 2/3 Not yet recruiting 40 enrolled Assaf-Harofeh Medical Center
RandomizedCrossoverTriple-blindTreatment

Summary

The study is designed to diminish intra-dialytic hypertension in chrnic hemodialysis patients suffering from metabolic acidosis (low bicarbonate levels). The intervention is a tab of 500 mg sodium bicarbonate twice a day for one month, vs. placebo.

Timeline

Start
2025-11-10
Primary completion
2027-12-01
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject sodium bicarbonate Diagnostic / imaging agent 500 mg Oral

Indications